Mountain State Medical Policy Bulletin

Section: Surgery
Number: S-147
Topic: Epithelial Cell Cytology in Breast Cancer Risk Assessment and High-Risk Patient Management (Ductal Lavage and Suction Collection Systems)
Effective Date: January 15, 2007
Issued Date: January 15, 2007
Date Last Reviewed: 11/2006

General Policy Guidelines

Indications and Limitations of Coverage

Techniques for collecting nipple aspiration fluid for cytologic analysis of epithelial cells in breast cancer risk assessment and high-risk patient management are considered investigational/experimental.  Techniques for collecting nipple aspiration fluid include, but are not limited to, ductal lavage (0046T, 0047T) and suction (19499).  There is insufficient evidence in medical literature to support the effectiveness of these procedures.  More studies are needed in order to determine whether these procedures will have an effect on outcomes.  A participating, preferred, or network provider can bill the member for the denied services.

Description

The majority of all breast cancers begin in the cells lining the milk ducts.  These cells may show the first signs of cancer months or even years before a tumor can be seen on a mammogram or felt in a physical exam.  Different collection systems have been investigated as techniques to obtain nipple aspirates; the collected epithelial cells are then examined cytologically.  These techniques have been evaluated as a diagnostic and risk assessment tool in patients at high risk of breast cancer, but without clinical or mammographic findings.  For example, the finding of atypical hyperplasia may be associated with an increased risk of breast cancer.  Malignant cells may also be identified in rare cases.  Ductal lavage and suction should only be used in addition to mammography and physical examination and after risk assessment shows the patient is at increased risk of developing breast cancer.

Ductal lavage is a minimally invasive procedure that involves several steps and takes approximately 30 minutes.  First, after an anesthetic cream is applied to the nipple, using a nipple aspirator, a small amount of nipple aspirate fluid (NAF) is elicited to locate fluid-yielding ducts for lavage.  Next, a microcatheter is inserted into each NAF-yielding duct through its natural opening on the nipple surface.  Saline is infused through the microcatheter into the duct to collect epithelial cells.  The ductal fluid is then withdrawn through the catheter and deposited into a collection vial.  The fluid is then analyzed microscopically for cytologic abnormalities.

When a suction system is used for nipple aspiration, small breast cups are placed on the woman's breast and adjusted to fit.  The system is then engaged and automatically warms the breast and applies light suction to bring nipple aspirate fluid to the surface.  Similar to ductal lavage, the fluid is then analyzed microscopically for cytologic abnormalities.


NOTE:
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

Procedure Codes

194990046T0047T   

Traditional Guidelines

Refer to General Policy Guidelines

FEP Guidelines

This medical policy may not apply to FEP.  Medical policy is not an authorization, certification, explanation of benefits or a contract.  Benefits are determined by the Federal Employee Program.

PPO Guidelines

Refer to General Policy Guidelines

Managed Care POS Guidelines

Refer to General Policy Guidelines

Publications

References

Identification of Pre-Malignant and Malignant Breast Cells by Ductal Lavage: Results from a Multicenter Trial, Proceedings ASCO 2000; 19: 76a Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer, The Journal of the National Cancer Institute, Volume 93, No. 21, 11/2001

Ductal Lavage and the Clinical Management of Women at High Risk for Breast Carcinoma, Cancer, Volume, 94, No. 2, 01/2002

Breast Cancer Risk in Women with Abnormal Cytology in Nipple Aspirates of Breast Fluid, Journal of the National Cancer Institute, Volume 93, No. 23, 12/2001

Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspirate Cytology and the Gail Risk Model, The Journal of the National Cancer Institute, Volume 92, No. 15, 08/2000

The Role of Tamoxifen in Breast Cancer Prevention, Annals of the New York Academy of Sciences, 12/2001

Ductal Lavage, Nipple Aspiration, and Ductoscopy for Breast Cancer Diagnosis, Current Oncology Reports, Volume 5, No. 1, 01/2003

Ductal Lavage in the Screening of High-Risk Women, Current Women's Health Reports, Volume 3, No. 2, 04/2003

Ductal Lavage; Clinical Utility and Future Promise, Surgical Clinics of North America, Volume 83, No. 4, 08/2003

Assessment of Utility of Ductal Lavage and Ductoscopy in Breast Cancer - A Retrospective Analysis of Mastectomy Specimens, Modern Pathology, Volume 16, No. 3, 03/2003

Ductal Lavage in Patients Undergoing Mastectomy for Mammary Carcinoma, A Correlative Study, Cancer, Volume 98, No. 10, 11/2003

Patterns of Reduced Nipple Aspirate Fluid Production and Ductal Lavage Cellularity in Women at High Risk for Breast Cancer, Breast Cancer Research, Volume 7, No. 6, 10/2004

Paired Ductal Lavage and Fine Needle Aspiration Specimens from Patients with Breast Carcinoma, Diagnostic Cytopathology, Volume 33, No. 6, 12/2005

Cytomorphology as a Risk Predictor:  Experience with Fine Needle Aspiration Biopsy, Nipple Fluid Aspiration, and Ductal Lavage, Clinics in Laboratory Medicine, Volume 25, No. 4, 12/2005

National Blue Cross and Blue Shield Association Medical Policy 2.01.45, Epithelial Cell Cytology in Breast Cancer Risk Assessment and High-Risk Patient Management (Ductal Lavage and Suction Collection Systems), 5:2005

View Previous Versions

[Version 002 of S-147]
[Version 001 of S-147]

Table Attachment

Text Attachment

Procedure Code Attachment


Glossary





This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

Medical policies are designed to supplement the terms of a member's contract. The member's contract defines the benefits available; therefore, medical policies should not be construed as overriding specific contract language. In the event of conflict, the contract shall govern.

Medical policies do not constitute medical advice, nor the practice of medicine. Rather, such policies are intended only to establish general guidelines for coverage and reimbursement under Mountain State Blue Cross Blue Shield plans. Application of a medical policy to determine coverage in an individual instance is not intended and shall not be construed to supercede the professional judgment of a treating provider. In all situations, the treating provider must use his/her professional judgment to provide care he/she believes to be in the best interest of the patient, and the provider and patient remain responsible for all treatment decisions.

Mountain State Blue Cross Blue Shield (MSBCBS) retains the right to review and update its medical policy guidelines at its sole discretion. These guidelines are the proprietary information of MSBCBS. Any sale, copying or dissemination of the medical policies is prohibited; however, limited copying of medical policies is permitted for individual use.